Company intelligence / Profile preview
Tyra Biosciences
Carlsbad, California, United Statestyra.bio ↗
- Ownership
- Public · TYRA
- Employees
- ~59
- Development stage
- Phase 2
01
Overview
TYRA-300 has shown high anti-tumor activity with favorable tolerability in heavily pre-treated cancer patients in the SURF301 study. The company has received FDA clearance for three INDs and is advancing TYRA-300 into three Phase 2 studies for different indications.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Financials
- Market cap
- $1.2B
- Total revenue
- $0
- Enterprise value
- $898M
Beyond the preview
Go deeper on Tyra Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyra Biosciences.